Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 19th Preview)
-
FDA approvals and new RNAi product launches
Regeneron’s RNAi therapy cemdisiran (renamed Livsayis) has received FDA approval for generalized myasthenia gravis, adding a second new MG drug approval in under a week. The launch extends Regeneron’s RNAi platform into a neurologic autoimmune setting and creates a new competitive benchmark for rapid-onset, targeted immunomodulation. The approval also signals a broader shift toward gene-silencing modalities in autoimmune disease, following Regeneron’s earlier RNAi entry points in immunology. For clinicians and payers, the key near-term question will be how rapidly cemdisiran’s real-world safety and durability profile can be established outside trial populations. Taken together with Regeneron’s pipeline updates around autoimmune CAR-T work, the move reframes the company’s development priorities: pairing late-stage RNAi commercialization with near-term expansion of cell-therapy optionality in inflammatory disease. For the market, Livsayis’ arrival tightens the timeline for differentiation versus established antibody and small-molecule options, particularly where disease-control speed and treatment logistics are central decision factors.
-
Big Pharma licensing for in vivo CAR-T in autoimmunity
Pfizer has signed a licensing deal with Starna Therapeutics worth $2.6 billion to expand its inflammation and immunology pipeline through in vivo CAR-T programs aimed at autoimmune diseases. Pfizer will pay $330 million upfront and could deliver up to $2.3 billion in development and commercial milestones. Under the agreement, Pfizer gains exclusive rights outside Mainland China, Hong Kong, Macau, and Taiwan to develop, manufacture, and commercialize up to three pre-IND in vivo CAR-T programs. The company will also use Starna’s proprietary targeted lipid nanoparticle RNA delivery and in vivo CAR-T technology, with Pfizer planning to lead clinical development. Starna, which positions its lipid nanoparticle delivery platform as a foundation for scalable immune engineering, will see Pfizer lead execution through its U.S. facilities. The structure also leaves room for Pfizer to optionally license compounds from a separate research collaboration. For the biotech sector, the deal underscores how large pharma is moving to de-risk platform assets for next-generation cell-therapy-like mechanisms that may be delivered as RNA payloads—potentially simplifying manufacturing and patient logistics compared with ex vivo autologous approaches.
-
Capital formation for AI-driven drug discovery
Isomorphic Labs has closed an oversubscribed $5 billion Series C to scale its AI drug-design engine, IsoDDE, and expand a growing therapeutic candidate pipeline toward clinical testing. The round follows a $1.2 billion Series B six months earlier and further underscores how venture capital is accelerating compute- and simulation-heavy approaches to small-molecule discovery. The financing is co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and continued investment from Alphabet and prior backers. Isomorphic says the funds will support scaling the core design engine, broadening model coverage, and building translational and clinical infrastructure to support rapid candidate iteration. In parallel, Merck has entered a research collaboration with Isomorphic to discover small-molecule oncology candidates for an undisclosed “strategic importance” target. The structure places Merck in control of preclinical/clinical development, manufacturing, and commercialization, while Isomorphic provides proprietary drug-design capabilities. Together, the two moves suggest platform validation is increasingly driven by both mega-round funding and pharma partnerships that translate model outputs into preclinical development pipelines.
-
Immunotherapy safety signals in CAR T – persistent cells driving gut toxicity
A Nature Medicine study reports that severe gut complications after CAR T therapy in multiple myeloma are linked to persistent CAR T cells accumulating in the digestive tract. The work ties a mechanistic driver—continued immune cell presence in the gut—to a clinically meaningful adverse-event phenotype. The findings reinforce the need to distinguish transient on-target activity from prolonged persistence in tissues when managing GI toxicities and optimizing patient selection. For translational teams, the study also highlights potential avenues for monitoring strategies that track spatial persistence rather than relying only on systemic biomarkers. Clinically, the report may influence how teams think about risk stratification for GI complications, especially in heavily pretreated populations where CAR T expansion and trafficking may behave differently. For the CAR T ecosystem, the message is clear: next-generation protocols and supportive-care regimens may need to address not just immune activation, but tissue residency over time.
-
CAR-T platform and clinical pipeline review updates at Novartis
Novartis disclosed a mid-stage eczema drug win and detailed its autoimmune CAR-T restart plans after a rocky quarter, while trimming the upper end of its sales-growth guidance through 2031. The update frames eczema progress as a near-term momentum driver and positions autoimmune cell therapy as a strategic rebuild following earlier setbacks. The company’s commentary ties operating focus to inflammation and immunology execution, with CAR-T work centered on resuming activity and refining development steps. For investors, the guidance tweak points to continued caution around the timing and scale of future launches. The ecosystem-level takeaway is that large-platform cell therapy programs remain sensitive to execution milestones and that eczema remains an important value lever for Novartis’ dermatology and immunology pipeline. In practical terms, the next catalysts for investors and clinicians will likely be updated trial timelines for autoimmune CAR-T and confirmatory readouts for eczema efficacy and safety.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.